Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II dasatinib-based chemotherapy and allogeneic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia
jRCTs031180284Phase 2Completed
- Start
- Oct 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dasatinib in acute lymphoblastic leukemia (ALL), mixed phenotype acute leukemia (MPAL) and chronic myelogenous leukemia (CML). Primary endpoint: overall response. Started Oct 2016; status: completed.
02
Drugs
dasatinib
03
Conditions
acute lymphoblastic leukemia (ALL)mixed phenotype acute leukemia (MPAL)chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on jRCTs031180284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180284.